What is the recommended treatment regimen for Still's disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment of Still's Disease

IL-1 or IL-6 inhibitors should be initiated as early as possible when Still's disease is diagnosed, combined with short-term glucocorticoids that are rapidly tapered to avoid prolonged exposure. 1

First-Line Treatment Strategy

The 2024 EULAR/PReS guidelines fundamentally changed the treatment paradigm for Still's disease (encompassing both systemic juvenile idiopathic arthritis and adult-onset Still's disease, now unified under one name). Biologic DMARDs targeting IL-1 or IL-6 should be prioritized from diagnosis rather than relying on prolonged glucocorticoid monotherapy 1, 2.

Initial Therapy Components:

  • IL-1 inhibitors (anakinra, canakinumab, rilonacept) OR IL-6 inhibitors (tocilizumab) as anchor therapy
  • Glucocorticoids: High-dose (≥1 mg/kg/day prednisone equivalent) may be used initially for severe symptoms, but the goal is rapid tapering
  • NSAIDs: Limited to symptomatic management during diagnostic workup only 1

The evidence strongly supports this approach: IL-1 and IL-6 inhibitors demonstrate the highest level of efficacy and safety with the most favorable risk-benefit ratio compared to all alternatives 2. Among IL-1 inhibitors, anakinra appears to have the most reassuring safety profile 1.

Treatment Targets and Timeline

The ultimate goal is drug-free remission, achieved through a treat-to-target approach with specific milestones 1:

  • Day 7: Resolution of fever + CRP reduction >50%
  • Week 4: No fever, active joint count reduced >50%, normal CRP, physician/patient global assessment <20/100
  • Month 3: Clinically inactive disease with glucocorticoids <0.2 mg/kg/day (children) or <0.1 mg/kg/day (adults)
  • Month 6: Clinically inactive disease WITHOUT glucocorticoids

Clinically inactive disease is defined as absence of Still's disease symptoms AND normal ESR or CRP. Remission requires maintaining clinically inactive disease for ≥6 months 1.

Choosing Between IL-1 and IL-6 Inhibitors

Start with either IL-1 or IL-6 inhibitor based on availability and clinical presentation 1. However:

  • IL-1 inhibitors show lower rates of serious adverse events and infections compared to IL-6 inhibitors 1
  • IL-6 inhibitors may be preferred for patients with prominent joint involvement 3
  • Switch to the alternative class (IL-1 to IL-6 or vice versa) if inadequate response, intolerance, or treatment failure occurs 3, 4

Important caveat: IL-6 inhibitors may blunt CRP elevation, which can mask disease activity or complications like MAS 1.

Role of Conventional DMARDs

Conventional synthetic DMARDs have marginal efficacy and should NOT be first-line 2:

  • Methotrexate: Failed to show superiority over placebo in the only RCT (even at ACR30 threshold) 1
  • Consider methotrexate or other csDMARDs only in countries where IL-1/IL-6 inhibitors are unavailable 1, 5
  • May serve as glucocorticoid-sparing agents in resource-limited settings, but biologics remain superior 1

Tapering and Discontinuation

Once clinically inactive disease is achieved:

  1. Maintain CID for 3-6 months WITHOUT glucocorticoids before considering biologic tapering 1
  2. Drug tapering or discontinuation may be considered in patients with sustained clinical and laboratory remission on IL-1 inhibitors 3
  3. Never use glucocorticoids to maintain disease control - if GC-dependence develops, add or switch biologics 1

Management of Macrophage Activation Syndrome (MAS)

MAS is a life-threatening complication requiring immediate recognition and treatment 1:

Suspect MAS with:

  • Persistent fever
  • Splenomegaly
  • Elevated/rising ferritin
  • Inappropriately low cell counts
  • Abnormal liver function tests
  • Coagulation abnormalities
  • Elevated/rising triglycerides

MAS Treatment:

High-dose glucocorticoids PLUS anakinra, ciclosporin, and/or IFN-γ inhibitors (emapalumab) as initial combination therapy 1, 2. This represents the best available strategy despite limited data 2.

Refractory Disease

For patients failing initial IL-1 or IL-6 inhibitor:

  1. Switch to the alternative class (IL-1↔IL-6) 3, 4
  2. TNF inhibitors may be considered for prominent joint involvement after IL-1/IL-6 failure 3
  3. JAK inhibitors represent emerging options for later-line therapy 4, 6

Critical Pitfalls to Avoid

  • Do NOT use prolonged glucocorticoid monotherapy - this causes severe side effects (growth retardation in children, metabolic syndrome in adults) without addressing underlying disease 1
  • Do NOT delay biologic initiation - early use improves outcomes and limits glucocorticoid exposure 1
  • Do NOT rely on methotrexate as primary therapy - evidence shows marginal efficacy 2
  • Do NOT miss MAS - maintain high vigilance throughout disease course, even during remission 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.